Earnings Feed
Start Free
Vor Biopharma Inc.·4

Apr 10, 6:23 PM ET

RA Capital Healthcare Fund LP 4

Research Summary

AI-generated summary

Updated

Vor Biopharma (VOR) 10% Owner RA Capital Sells Shares

What Happened
RA Capital Management, L.P. (a reported 10% owner and investment manager to RA Capital Healthcare Fund, L.P.) sold a total of 620,133 shares of Vor Biopharma (VOR) common stock in open-market/private sales between April 8 and April 10, 2026. The four reported transactions were:

  • 353,242 shares at a weighted-average $16.32 — $5,764,909 (footnote: prices in this lot ranged $15.755–$16.68).
  • 130,862 shares at a weighted-average $16.91 — $2,212,876 (footnote: range $16.755–$16.975).
  • 135,201 shares at a weighted-average $16.59 — $2,242,985 (footnote: range $15.94–$16.385).
  • 828 shares at a weighted-average $15.75 — $13,041 (footnote: range $15.75–$15.76).
    Total proceeds reported across these sales: approximately $10.23 million. These were sales (not purchases), which are commonly portfolio or liquidity actions for institutional holders.

Key Details

  • Transaction dates: Apr 8, 2026 (two blocks), Apr 9, 2026, and Apr 10, 2026. Weighted-average prices reported per block; footnotes indicate each block was executed in multiple trades across the stated price ranges.
  • Shares sold: 620,133 total; total proceeds ≈ $10,233,811.
  • Shares owned after transaction: not specified in the excerpt provided. The filing notes the sold shares were held directly by the Fund.
  • Reporting structure/footnotes: RA Capital Management, L.P. is the Adviser to the Fund; RA Capital and related parties disclaim beneficial ownership except for pecuniary interest. The filing includes footnotes offering to provide breakdowns of the multiple execution prices on request.
  • Board connection: Dr. Andrew Levin, a Partner/Managing Director of the Adviser, serves on Vor Biopharma’s board (disclosed in the filing).
  • Filing timeliness: Form 4 was filed Apr 10, 2026 for trades Apr 8–10; no late filing is indicated in the report.

Context

  • This is institutional/10%-owner selling, not necessarily an executive insider’s personal trade. Institutional sales can reflect portfolio rebalancing or liquidity needs and are not direct signals about company fundamentals.
  • The filing reports weighted-average prices and provides price ranges per block (the reporting persons offer to provide per-trade price details on request).
  • No option exercises, awards, gifts, or 10b5-1 plan disclosures are noted in the provided excerpt.